## **Supplementary Information**

## Suppressed autophagic response underlies augmentation of renal ischemia/reperfusion injury by type 2 diabetes.

Shingo Muratsubaki, Atsushi Kuno<sup>+</sup>, Masaya Tanno, Takayuki Miki, Toshiyuki Yano, Hirohito Sugawara, Satoru Shibata, Koki Abe, Satoko Ishikawa, Kouhei Ohno, Yukishige Kimura, Yuki Tatekoshi, Kei Nakata, Wataru Ohwada, Masashi Mizuno, Tetsuji Miura

Department of Cardiovascular, Renal and Metabolic Medicine, †Department of Pharmacology, Sapporo Medical University School of Medicine, Sapporo, Japan.

				· 1	_
	LETO	OLETF	LETO+CQ	OLETF+CQ	
	(N=12)	(N=12)	(N=8)	(N=10)	
Heart rate (bpm)	349±4	277±12*	307±10*	260±9 <sup>#</sup>	-
Systolic blood pressure (mmHg)	104±3	104±2	108±3	117±3 <sup>#†</sup>	
Diastolic blood pressure (mmHg)	72±4	70±3	66±2	79±2 <sup>#</sup> †	

Supplementary Table 1. Hemodynamic parameters 24 h after renal ischemia/reperfusion

Values are means ± SEM. \*p<0.05 vs. LETO, <sup>#</sup>P<0.05 vs. LETO+CQ, <sup>†</sup>P<0.05 vs. OLETF

	OLETF+ Vehicle	OLEFT+ Rapamycin
	(N=7)	(N=7)
Body weight (g)	641±12	650±16
Blood glucose (mg/dl)	231±21	234±20
Glycoalbumin (%)	17.2±3.0	14.0±1.3
Total cholesterol (mg/dl)	144±9	155±15
Triglyceride (mg/dl)	147.6±48.5	148.0±33.0

**Supplementary Table 2.** Effect of rapamycin on metabolic parameters after renal ischemia/reperfusion.

Values are means ± SEM.

	OLETF+ Vehicle	OLEFT+ Rapamycin	
	(N=7)	(N=7)	
Heart rate (bpm)	306±14	285±10	
Systolic blood pressure (mmHg)	122±4	121±3	
Diastolic blood pressure (mmHg)	85±7	78±3	

**Supplementary Table 3.** Effects of rapamycin on hemodynamic parameters after renal ischemia/reperfusion

Values are means ± SEM.

Supplementally Table 4. Antibodies used in the present study							
Antibodies	Source	Cat. No.	dilution				
Guinea pig anti-polyclonal p62	Progen	GP62-C	1:1000				
Rabbit monoclonal anti-LC3A/B	Cell Signaling	#12741	1:1000				
Rabbit polyclonal anti-phospho-Thr389-p70S6K	Cell Signaling	#9205	1:1000				
Rabbit polyclonal anti-p70S6K	Cell Signaling	#9202	1:1000				
Rabbit polyclonal anti-phospho-Ser235/236-S6	Cell Signaling	#2211	1:1000				
Rabbit polyclonal anti-S6	Cell Signaling	#2217	1:1000				
Rabbit polyclonal anti-phospho-Ser473-Akt	Cell Signaling	#9271	1:1000				
Rabbit polyclonal anti-Akt	Cell Signaling	#9272	1:1000				
Rabbit monoclonal anti-phospho-Thr172	Coll Signaling	#2535	1.1000				
ΑΜΡΚα		π2555	1.1000				
Rabbit polyclonal anti-AMPK $lpha$	Cell Signaling	#2532	1:1000				
Rabbit monoclonal anti-phospho-Ser555-ULK1	Cell Signaling	#5869	1:1000				
Rabbit monoclonal anti-ULK1	Abcam	ab128859	1:1000				
Rabbit monoclonal anti-Beclin-1	Cell Signaling	#3495	1:1000				
Mouse monoclonal anti-p53 (1C12)	Cell Signaling	#2524	1:1000				
Mouse monoclonal anti-SIRT1 (19A7AB4)	Abcam	ab110304	1:2000				
Mouse monoclonal anti-β-actin	Sigma-Aldrich	A5316	1:10000				

## **Supplementary Table 4**. Antibodies used in the present study



**Supplementary Figure 1.** Sizes of glomerular areas and mesangial areas in LETO and OLETF. Representative glomeruli stained with PAS (A) and group mean data for glomerular area size (B) and for mesangial area size (C). Fifteen glomeruli were randomly selected in each kidney sample and sizes of glomerular and mesangial areas were determined by Nikon NIS-elements software. N = 5 in each group. \*P<0.05. Scale bar, 50 μm.



**Supplementary Figure 2.** Protein levels of p53 in LETO and OLETF before and after renal ischemia/reperfusion.Left panel: Representative immunoblots for p53 before ischemia (Pre) and 24 h after ischemia/reperfusion (I/R). Right panel: group mean data for p53 protein level normalized by  $\beta$ -actin level (n = 8 in each treatment group).